What does GlobeImmune, Inc. do?

GlobeImmune, Inc. (GBIM) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is GBIM's market cap?

GlobeImmune, Inc. (GBIM) has a market capitalization of approximately $575, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does GBIM pay a dividend?

No — GlobeImmune, Inc. (GBIM) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

GlobeImmune, Inc. (GBIM) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

GBIM

GlobeImmune, Inc.

OTC·Biotechnology · Healthcare

$0.00$0.00+0.00%

Market cap$575.00·Market closed·Aug 26 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−99.97%CAGR −80.45%

Select date range

FromTo

Jul 2, 2014Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

GBIM does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateMay 12

Last Report DateMay 12

Reported vs Estimate−$0.15

Earnings Surprise—

FinancialsFinancials Tab

Revenue$6.21M

Net Income−$2.07M

Net Margin−33.3%

Operating Cash Flow−$5.90M

Capital Expenditures$11.81K

Free Cash Flow−$5.92M

Return on Equity−96.2%

Return on Invested Capital−15.3%

Net Cash$8.69M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for GBIM and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how GBIM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GBIM and 80,000+ other tickers.

About GlobeImmune, Inc.

GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally…

CEO: Donald Bellgrau
Sector: Healthcare
Industry: Biotechnology
Exchange: OTC
Employees: 2
Website: www.globeimmune.com

Peers

Peers Tab

SYVC

Synovics Pharmaceuticals, Inc.

Cap

$3.0K

NTII

Neurobiological Technologies, Inc.

Cap

$2.7K

CMRA

Comera Life Sciences Holdings, Inc.

Cap

$3.1K

Latest News

News Tab

No recent news available.

Frequently Asked Questions About GBIM

What does GlobeImmune, Inc. do?: GlobeImmune, Inc. (GBIM) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is GBIM's market cap?: GlobeImmune, Inc. (GBIM) has a market capitalization of approximately $575, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does GBIM pay a dividend?: No — GlobeImmune, Inc. (GBIM) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is GBIM profitable?: GlobeImmune, Inc. (GBIM) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.